The Discounted Cash Flow (DCF) valuation of Tekla Life Sciences Investors (HQL) is 52.19 USD. With the latest stock price at 12.35 USD, the upside of Tekla Life Sciences Investors based on DCF is 322.6%.
Based on the latest price of 12.35 USD and our DCF valuation, Tekla Life Sciences Investors (HQL) is a buy. buying HQL stocks now will result in a potential gain of 322.6%.
| Range | Selected | |
| WACC / Discount Rate | 6.3% - 7.4% | 6.8% |
| Long-term Growth Rate | 0.0% - 1.0% | 0.5% |
| Fair Price | 45.64 - 61.24 | 52.19 |
| Upside | 269.5% - 395.9% | 322.6% |